Skip to main content

OncoMethylome, GSK Agree on Possible Use of DNA Methylation Biomarker

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – OncoMethylome Sciences today announced an agreement with GlaxoSmithKline Biologics for the potential use of a DNA methylation-specific biomarker for the development of immunotherapeutics.

The two firms began a collaboration in 2007, and today's agreement "marks an important step for our company in the use of our biomarker with certain immunotherapeutics in development by GSK," said Jan Groen, CEO of OncoMethylome. He added that it "underpins our strategy of leveraging our methylation-specific PCR platform" for the development of companion diagnostics and personalized medicine.

The biomarker, the Belgian company said, allows for the analysis of non-invasive tissue samples.

Financial terms of the agreement were not disclosed.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.